原发性干燥综合征女性的妊娠结局:多中心前瞻性GR2研究数据分析
该多中心前瞻性队列研究纳入96例原发性干燥综合征女性的106次妊娠,与法国一般人群匹配对照比较,不良妊娠结局风险无显著增加(OR 1.31,95%CI 0.53-2.98,p=0.52);抗磷脂抗体阳性者不良结局更常见,作者认为需密切监测。
要点
- 原发性干燥综合征女性不良妊娠结局风险与一般人群无显著差异(OR 1.31,95%CI 0.53-2.98,p=0.52)。
- 93次妊娠中12次(13%)发生疾病 flares,无基线参数与 flares 相关。
- 抗磷脂抗体阳性妊娠不良结局比例更高(2/4 vs 2/51,p=0.023)。
核心结论
- 原发性干燥综合征女性的妊娠母婴预后良好,不良妊娠结局风险较一般人群无总体增加。
- 作者认为抗磷脂抗体或抗RNP抗体阳性女性需密切监测,因这些因素可能与不良妊娠结局风险较高相关。
研究设计与样本
- 法国多中心前瞻性队列研究,使用GR2登记处,纳入2021年3月前受孕、符合2016年ACR/EULAR原发性干燥综合征分类标准且妊娠12周时仍在妊娠的女性。
- 共识别1944次妊娠,最终分析纳入96例女性的106次妊娠。
- 匹配对照研究比较GR2登记处原发性干燥综合征妊娠与法国围产期调查(Enquête Nationale Périnatale 2016)匹配对照的不良妊娠、分娩和出生结局率。
主要发现
- 妊娠起病中位年龄33岁(IQR 31-36);105次有族裔数据的妊娠中87次(83%)为白人女性,18次(17%)为黑人女性。
- 102次妊娠中92次(90%)既往有全身活动(ESSDAI评分≥1;4次妊娠数据缺失),106次妊娠中48次(45%)纳入时有全身活动。
- 93次妊娠在孕18周或更早纳入,其中12次(13%)发生原发性干燥综合征 flares。
- 排除4次双胎妊娠和1次医疗终止后,88次妊娠中6次(7%)发生不良妊娠结局。
- 55次有抗磷脂抗体数据的妊娠中,不良结局妊娠抗磷脂抗体阳性2/4(50%),无不良结局妊娠阳性2/51(4%),p=0.023。
关键数值与推荐
- 原发性干燥综合征 flare 定义为ESSDAI评分较基线增加≥3分。
- 不良妊娠结局定义为胎儿或新生儿死亡、胎盘功能不全导致早产(妊娠<37周)或小于胎龄儿出生体重。
- 匹配对照研究不良妊娠结局:原发性干燥综合征妊娠9/105(9%)vs 匹配对照妊娠28/420(7%),OR 1.31(95%CI 0.53-2.98),p=0.52。
- 抗磷脂抗体阳性妊娠不良结局2/4(50%)vs 抗磷脂抗体阴性妊娠2/51(4%),p=0.023。
临床怎么用
- 原文未据此给出推荐。
- 作者认为抗磷脂抗体或抗RNP抗体阳性女性需密切监测,因这些因素可能与不良妊娠结局风险较高相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adverse pregnancy outcomes in women with primary Sjögren's syndrome have only been evaluated retrospectively using heterogeneous methods and with contradictory results. We aimed to describe adverse pregnancy, delivery, and birth outcome risks in pregnant women with primary Sjögren's syndrome compared with those of a matched general population in France, and to identify factors predictive of disease flares or adverse pregnancy outcomes. METHODS: We conducted a multicentre, prospective, cohort study in France using the GR2 (Groupe de Recherche sur la Grossesse et les Maladies Rares) registry. Women from the GR2 study were eligible if they had conceived before March, 2021, had primary Sjögren's syndrome according to the American College of Rheumatology and European Alliance of Associations for Rheumatology (EULAR) 2016 classification criteria, and had an ongoing pregnancy at 12 weeks of gestation. In women who entered in the registry with pregnancies before 18 weeks of gestation, we sought to identify factors associated with primary Sjögren's syndrome flare (≥3-point increase in EULAR Sjögren's Syndrome Disease Activity Index [ESSDAI] score) or adverse pregnancy outcomes (fetal or neonatal death, placental insufficiency leading to a preterm delivery [<37 weeks of gestation], or small-for-gestational-age birthweight). A matched controlled study compared adverse pregnancy, delivery, and birth outcome rates between pregnant women with primary Sjögren's syndrome from the GR2 registry and matched controls from the general population included in the last French perinatal survey (Enquête Nationale Périnatale 2016). FINDINGS: 1944 pregnancies were identified in the GR2 cohort, of which 106 pregnancies in 96 women with primary Sjögren's syndrome were included in this analysis. The median age at pregnancy onset was 33 years (IQR 31-36). 87 (83%) of 105 pregnancies (with ethnicity data) were in White women, 18 (17%) were in Black women; 92 (90%) of 102 had previous systemic activity (ESSDAI score of ≥1; data missing in four pregnancies), and 48 (45%) of 106 had systemic activity at inclusion. Of 93 pregnancies included at week 18 of gestation or earlier, primary Sjögren's syndrome flares occurred in 12 (13%). No baseline parameters were associated with primary Sjögren's syndrome flare. Four twin pregnancies and one medical termination were excluded from the adverse pregnancy outcome analysis; of the remaining 88, adverse pregnancy outcomes occurred in six (7%). Among pregnancies in women with data for antiphospholipid antibodies (n=55), antiphospholipid antibody positivity was more frequent among pregnancies with adverse outcomes (two [50%] of four pregnancies) compared with those without adverse outcomes (two [4%] of 51 pregnancies; p=0·023). Anti-RNP antibody positivity was also more frequent among pregnancies with adverse outcomes than those without, although this was not statistically significant. In the matched controlled study, adverse pregnancy outcomes occurred in nine (9%) of 105 pregnancies in women with primary Sjögren's syndrome and 28 (7%) of the 420 matched control pregnancies; adverse pregnancy outcomes were not significantly associated with primary Sjögren's syndrome (odds ratio 1·31, 95% CI 0·53-2·98; p=0·52). INTERPRETATION: Pregnancies in women with primary Sjögren's syndrome had very good prognoses for mothers and fetuses, with no overall increase in adverse pregnancy outcome risk compared with the general population. Women with antiphospholipid antibodies or anti-RNP antibodies require close monitoring, because these factors might be associated with a higher risk of adverse pregnancy outcomes. FUNDING: Lupus France, Association des Sclérodermiques de France, Association Gougerot Sjögren, Association Francophone Contre la Polychondrite Chronique Atrophiante, AFM-Telethon, Société Nationale Française de Médecine Interne, Société Française de Rhumatologie, Cochin Hospital, French Health Ministry, Fondation for Research in Rheumatology, Association Prix Véronique Roualet, Union Chimique Belge.
引用
- de Frémont GM, Costedoat-Chalumeau N, Lazaro E, et al. Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study. Lancet Rheumatol. 2023. PMID: 38251600. doi:10.1016/S2665-9913(23)00099-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。